Premium
Clinical and pathologic risk factors of tumor recurrence in patients with node‐negative early breast cancer after mastectomy
Author(s) -
Lin PoHan,
Yeh MingHsin,
Liu LiangChih,
Chen ChihJung,
Tsui YuChu,
Su ChenHsien,
Wang HweiChung,
Liang JiAn,
Chang HuiWen,
Wu HsiaoSu,
Yeh SuPeng,
Li LongYuan,
Chiu ChangFang
Publication year - 2013
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23403
Subject(s) - medicine , lymphovascular invasion , radiation therapy , mastectomy , breast cancer , hazard ratio , oncology , cancer , chemotherapy , adjuvant radiotherapy , adjuvant therapy , surgery , metastasis , confidence interval
Background and Objectives Patients with node‐negative breast cancer (NNBC) usually have a good prognosis, but tumor recurrence still compromises survival. In this study, we sought to identify clinical and pathologic factors that predict recurrence. Methods A total of 716 patients who were proved with pT1‐2N0M0 breast cancer between 2005 and 2009 were enrolled in this study. Results Forty‐seven of the 716 patients developed tumor recurrence during the 47.0 months of median follow‐up. The significant risk factors of recurrence were lymphovascular invasion (LVI) (hazard ratio [HR] = 4.60, 95% CI. 2.32–9.10) and Nottingham grade 3 (HR = 4.99, 95% CI. 1.06–23.48); adjuvant radiotherapy (HR = 0.35, 95% CI. 0.14–0.92) prevented tumor recurrence. Furthermore, we investigate the therapeutic impact of adjuvant chemotherapy and radiotherapy on patients with LVI and Nottingham grade 3. The adverse effect of LVI and grade 3 can be abrogated by adjuvant radiotherapy in recurrence‐free survival (RFS) (LVI (+) radiotherapy (+) , no recurrence; grade 3 (+) radiotherapy (+) , HR = 0.82, 95% CI. 0.18–3.70). However, adjuvant chemotherapy did not. Conclusions LVI and Nottingham grade 3 were the independent risk factors predicting tumor recurrence for patients with NNBC. Adjuvant radiotherapy might be considered in NNBC patients with these unfavorable factors to improve the RFS. J. Surg. Oncol. 2013; 108:352–357 . © 2013 Wiley Periodicals, Inc.